[2015 SLAS Conference Poster] BioMAP® Human Primary Cell Systems for Improving Drug Discovery and Development

[2015 SLAS Conference Poster] BioMAP® Human Primary Cell Systems for Improving Drug Discovery
and Development
File Name/Number:
2015 SLAS Conference Poster

Year:
2015

Improving the safety and efficacy of drug candidates that enter clinical development require assays that are more predictive of human outcomes. The BioMAP platform uses human primary cells to model complex aspects of disease and tissue biology and can be applied to better understand biological mechanisms that underlie drug efficacy and safety. Here we test Ibrutinib (PCI-32765), a Bruton’s tyrosine kinase (BTK) inhibitor approved by the US FDA for B-cell malignancies, for biomarker activities in a broad range of human biology by profiling in the Diversity PLUS™ panel of 12 BioMAP systems and compare its activity profile to that of a highly selective BTK inhibitor, GDC-0834, and other reference compounds in the BioMAP database.